UNSPSC 51333903: Quinagolide hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C20H33N3O3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33474X943Y, chemically known as sulfamide, n,n-diethyl-n-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)-, monohydrochloride, (3-alpha,4a-alpha,10a-beta)- but more generally known as quinagolide hydrochloride, which bears US NIH Compound Identifier 3086400.

UNSPSC 51333903 Quinagolide hydrochloride is a Commodity code that nominally describes a specific dopamine agonist pharmaceutical product, but the recent state and local solicitations tagged under this code show little alignment with that narrow scope. The three posted opportunities involve naloxone and drug deactivation systems (Seminole County, Florida), a pharmacy benefit management information-gathering request (Texas Health and Human Services Commission), and generic multi-source pharmaceutical and OTC product contracting through a multistate cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). These opportunities span health departments, HHS agencies, and cooperative purchasing consortiums rather than addressing a single active pharmaceutical ingredient, and they reflect state and local governments' recurring need to establish supply agreements for pharmaceuticals and related health products through competitive processes. The issuing bodies include county health departments, state health agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple participating jurisdictions.

The geographic spread includes Florida, Texas, and Minnesota with secondary reach into Oregon (a participant in the MMCAP cooperative). The most recent representative opportunity is Seminole County's IFB 60459723LAS, posted June 30, 2026, with response due July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building. The Minnesota MMCAP RFP (S1070000015802), posted January 20, 2026 with response due March 26, 2026, represents a larger multistate cooperative procurement establishing multiple contracts for generic pharmaceuticals and OTC products to be distributed through authorized wholesalers with pricing evaluated at 75 percent weight. The Texas HHS RFI (HHS0017013), posted April 3, 2026, is an early-stage information-gathering request exploring direct-to-manufacturer prescription fulfillment models. The code shows mixed activity and modest alignment with the nominal pharmaceutical ingredient scope; business development professionals should verify whether quinagolide-specific opportunities exist under different codes or whether this code has become a catch-all miscategorization in state procurement systems.